Xeris Biopharma Holdings, Inc. revenue
Xeris Biopharma Holdings, Inc.'s revenue was $292m in fiscal 2025, up 43.7% on the year before. Since fiscal 2020 ($20.4m) it has grown at a compound 70.2% a year. Over the last twelve months it was $335m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $283M | 97.0% | ▲ 43.9% |
| Recorlev (part of Products) | $139M | 49.2% | ▲ 116.7% |
| Gvoke (part of Products) | $94.1M | 33.3% | ▲ 13.6% |
| Keveyis (part of Products) | $47.6M | 16.8% | ▼ 3.8% |
| Product Other (part of Products) | $2M | 0.7% | — |
| Royalty Contract and Other Revenue | $8.8M | 3.0% | ▲ 37.4% |
From Xeris Biopharma Holdings, Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. | $335m | 36.3% | 35.8% |
| Evolus, Inc. | $316m | 13.9% | 23.4% |
| Ironwood Pharmaceuticals Inc | $389m | 26.2% | -3.1% |
| Harrow, Inc. | $276m | 21.1% | 39.0% |
| Innoviva, Inc. | $440m | 18.8% | 14.9% |
| Aurora Cannabis Inc | $232m | 11.7% | — |
Compare with peers
- Evolus, Inc. revenue
- Ironwood Pharmaceuticals Inc revenue
- Harrow, Inc. revenue
- Innoviva, Inc. revenue
- Aurora Cannabis Inc revenue
Head to head: EOLS vs XERSIRWD vs XERSHROW vs XERSINVA vs XERS
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies